Merck launches Circumvent PCV-M G2 vaccine

Published on: Jan 22, 2014

Merck Animal Health introduced Circumvent PCV-M G2 — a porcine circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae combination vaccine. The new vaccine is the only one-dose or two-dose, ready-to-use combination with five-month PCV2 duration of immunity, which is 25% longer than any other PCV2 vaccine on the market, the announcement said.

"The added four weeks of immunity that Circumvent G2 brings means better protection in late stages of production where the loss of pigs approaching market weight can be devastating," Dr. Brad Thacker, Merck Animal Health senior technical services veterinarian, said. "Now we're able to provide this protection in combination with M. hyo in an easy-to-use, one-bottle solution, which offers producers significant benefits."

The vaccine is the second product in the next generation of Circumvent G2 vaccines, which offer one- or two-dose options, giving producers and their veterinarians the flexibility to choose the dosing protocol that best fits their operation's needs.

With the two-dose option, producers can administer the first vaccination to piglets as early as three days of age, which helps get them off to a stronger start. Having the ability to vaccinate at such an early age also offers the added convenience of working smaller pigs that are easier to handle and less stressed, and this process can be completed by some of the operation's most trusted and capable pig handlers who commonly work in the farrowing barns.